Evolus, Inc. (EOLS) Reports Q3 Loss, Beats Revenue Estimates

Core Insights - Evolus, Inc. reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.19, marking an earnings surprise of +26.32% [1] - The company posted revenues of $68.97 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.70% and showing an increase from $61.08 million year-over-year [2] - Evolus shares have declined approximately 41.9% year-to-date, contrasting with the S&P 500's gain of 15.1% [3] Financial Performance - Over the last four quarters, Evolus has exceeded consensus EPS estimates only once [2] - The current consensus EPS estimate for the upcoming quarter is $0.12 on revenues of $91.18 million, while for the current fiscal year, it is -$0.48 on revenues of $297.1 million [7] Market Outlook - The company's earnings outlook and management's commentary during the earnings call will be crucial for future stock price movements [3][4] - The Zacks Rank for Evolus is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Industry Context - The Medical - Products industry, to which Evolus belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, which may impact stock performance [8] - Comparatively, ICU Medical, another company in the same industry, is expected to report a quarterly earnings decline of -3.1% year-over-year [9]